The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combination of eribulin with trastuzumab and pertuzumab for HER2 positive advanced or recurrent breast cancer: JBCRG­M03.
 
Toshinari Yamashita
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Nippon Kayaku; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Nihonkayaku (Inst); Taiho Pharmaceutical (Inst)
 
Hidetoshi Kawaguchi
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo Pharmaceutical; Eisai; Kyowa Kirin; Lilly O.; Maruho; Nippon Kayaku; Novartis; Pfizer; Taiho Pharmaceutical
 
Norikazu Masuda
Leadership - Japan Breast Cancer Research Group; Japanese Breast Cancer Society
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa-Kirin; Lilly Japan; Novartis; Pfizer; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Masahiro Kitada
No Relationships to Disclose
 
Kazutaka Narui
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; Pfizer
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Kirin International (Inst)
 
Masaya Hattori
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Lilly; MSD K.K; Pfizer
 
Tetsuhiro Yoshinami
Consulting or Advisory Role - Eisai
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo Pharmaceutical; Eisai; Kyowa Kirin; Lilly O.; MSD; Novartis; Pfizer
Research Funding - Lilly O.
 
Nobuki Matsunami
No Relationships to Disclose
 
Kazuhiro Yanagihara
No Relationships to Disclose
 
Takeshi Nagashima
No Relationships to Disclose
 
Hiroko Bando
No Relationships to Disclose
 
Hiroshi Yano
No Relationships to Disclose
 
Yoshie Hasegawa
No Relationships to Disclose
 
Rikiya Nakamura
Speakers' Bureau - AstraZeneca; Chugai Pharma; Lilly O.; Novartis
 
Masahiro Kashiwaba
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo Pharmaceutical; Lilly O.; Nihonkayaku; Taiho Pharmaceutical
 
Satoshi Morita
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Company; Chugai Pharma; Eisai; Lilly Japan; MSD K.K.; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer
Research Funding - Eisai (Inst)
 
Shinji Ohno
Speakers' Bureau - AstraZeneca; AstraZeneca; Chugai/Roche; Daiichi Sankyo/UCB Japan; Eisai; Kyowa Kirin International; Lilly Japan; Lilly Japan; MSD; Nihonkayaku; Nihonkayaku; Pfizer; Pfizer; Taiho Pharmaceutical
Research Funding - Eisai (Inst); Eisai (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Masakazu Toi
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Devicor Medical Products; Eisai; Exact Sciences; Kyowa Kirin; Lilly; MSD; Nippon Kayaku; Novartis; Pfizer; Shimadzu; Sysmex; Taiho Pharmaceutical; TAKEDA; Yakult Pharmaceutical
Consulting or Advisory Role - Athenex; Bertis; BMS; Daiichi Sankyo; Kansai Medical; Lilly; Terumo
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Lilly; Pfizer
Research Funding - AFI technology; Astellas Pharma; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; GL Sciences; Japan Breast Cancer Research Group; Kyoto Breast cancer Research Network; Lilly (Inst); Lux Biosciences; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Sanwa Shurui; Shimadzu; Shionogi; Taiho Pharmaceutical; Yakult Pharmaceutical
Patents, Royalties, Other Intellectual Property - JP 2017-143763 WO2017/131162A1 (Inst); PCT/JP2016/004374 (Inst)
Other Relationship - Asian Journal of Surgery; Asian Journal of Surgery; Breast Cancer research and Treatment; British Journal of Cancer; Cancer Science; Japan Breast Cancer Research Group; Japanese Breast Cancer Society; Kyoto Breast Cancer Research Network; Organization for Oncology and Translational Research; Scientific Reports